Advertisement
Research Article

Clinical, Epidemiologic, Histopathologic and Molecular Features of an Unexplained Dermopathy

  • Michele L. Pearson,

    Affiliation: Division of TB Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • Joseph V. Selby,

    Affiliation: Division of Research, Kaiser Permanente Northern California, Oakland, California, United States of America

    X
  • Kenneth A. Katz,

    Affiliation: HIV, STD, and Hepatitis Branch, Health and Human Services Agency, County of San Diego, San Diego, California, United States of America

    X
  • Virginia Cantrell,

    Affiliation: Division of Research, Kaiser Permanente Northern California, Oakland, California, United States of America

    X
  • Christopher R. Braden,

    Affiliation: Division of Food, Waterborne and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • Monica E. Parise,

    Affiliation: Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • Christopher D. Paddock,

    Affiliation: Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • Michael R. Lewin-Smith,

    Affiliation: Environmental Pathology, Joint Pathology Center, Silver Spring, Maryland, United States of America

    X
  • Victor F. Kalasinsky,

    Affiliation: Office of Research & Development, United States Department of Veterans Affairs, Washington, District of Columbia, United States of America

    X
  • Felicia C. Goldstein,

    Affiliation: Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, United States of America

    X
  • Allen W. Hightower,

    Affiliation: Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • Arthur Papier,

    Affiliation: Department of Dermatology, University of Rochester School of Medicine, Rochester, New York, United States of America

    X
  • Brian Lewis,

    Affiliation: Division of Health Studies, Agency for Toxic Substances and Disease Registry, Atlanta, Georgia, United States of America

    X
  • Sarita Motipara,

    Affiliation: Division of Research, Kaiser Permanente Northern California, Oakland, California, United States of America

    X
  • Mark L. Eberhard mail,

    mle1@cdc.gov

    Affiliation: Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • for the Unexplained Dermopathy Study Team

    Additional membership of the Unexplained Dermopathy Study Team is provided in the Acknowledgments.

    X
  • Published: January 25, 2012
  • DOI: 10.1371/journal.pone.0029908

Reader Comments (23)

Post a new comment on this article

Query about calculations

Posted by kiricat on 26 Jan 2012 at 20:00 GMT

The percentage calculations don't add up in the following paragraph (for example, 14 out of 24 patients is not 39%):

"Of the 24 case-patients with scores suggesting clinically significant somatic complaints, 14 (39%) had evidence of co-existing depression, 10 (37%) evidence of other co-existing neuropsychiatric conditions, and 12 (50%) had T scores >87, suggesting severe impairment arising from the somatic complaints. Four (24%) had evidence of clinically significant past or present drug or alcohol use."

The authors might want to double check all their published calculations.

No competing interests declared.